INTRODUCTION: Undernourishment on hospital admission has been considered as risk factor for complications and increased relapse/nonrelapse mortality in hematopoietic stem cell transplantation (HSCT) patients. MATERIALS AND METHODS: All patients undergoing HSCT are at an increased risk for malnutrition. The changes in these patients affect mainly protein, energy, and micronutrient metabolism. Nutrition support recommendations are now based on the nutritional status of the individual patient, and total parenteral nutrition is no longer indicated for all HSCT patients. As long as it is possible, an oral route should be use in feeding to avoid complications. When total parenteral nutrition (TPN) should be started is one of the most controversial issues. The following indications for TPN are now generally accepted: severe malnutrition at admission (BMI < 18.5) or weight loss > 10% during treatment or impossibility of oral feeding or failing to meet 60-70% of the requirements over 3 days. Specialized nutritional support containing glutamine or immunomodulatory formulas such as arginine, ω3 polyunsaturated fatty acids, purine/pyrimidines (RNA) may be useful. RESULT: The complications of TPN are divided into metabolic and those related to central venous catheter. TPN should be progressively decreased while increasing feedings by the oral route. When the patients can cover ≥50% of the daily energy requirements orally (for greater than 5 days), withdrawal of TPN may be appropriate. In patients who have suffered from graft-versus-host disease (GvHD) with intestinal involvement, TPN should be used until the stool volume decreases to <500 ml/day for at least 2 days. CONCLUSION: Parenteral nutrition allows better modulation of fluid, electrolytes, and nutrient administration which can be of critical importance when complications such as GvHD or VOD arise.
INTRODUCTION: Undernourishment on hospital admission has been considered as risk factor for complications and increased relapse/nonrelapse mortality in hematopoietic stem cell transplantation (HSCT) patients. MATERIALS AND METHODS: All patients undergoing HSCT are at an increased risk for malnutrition. The changes in these patients affect mainly protein, energy, and micronutrient metabolism. Nutrition support recommendations are now based on the nutritional status of the individual patient, and total parenteral nutrition is no longer indicated for all HSCT patients. As long as it is possible, an oral route should be use in feeding to avoid complications. When total parenteral nutrition (TPN) should be started is one of the most controversial issues. The following indications for TPN are now generally accepted: severe malnutrition at admission (BMI < 18.5) or weight loss > 10% during treatment or impossibility of oral feeding or failing to meet 60-70% of the requirements over 3 days. Specialized nutritional support containing glutamine or immunomodulatory formulas such as arginine, ω3 polyunsaturated fatty acids, purine/pyrimidines (RNA) may be useful. RESULT: The complications of TPN are divided into metabolic and those related to central venous catheter. TPN should be progressively decreased while increasing feedings by the oral route. When the patients can cover ≥50% of the daily energy requirements orally (for greater than 5 days), withdrawal of TPN may be appropriate. In patients who have suffered from graft-versus-host disease (GvHD) with intestinal involvement, TPN should be used until the stool volume decreases to <500 ml/day for at least 2 days. CONCLUSION: Parenteral nutrition allows better modulation of fluid, electrolytes, and nutrient administration which can be of critical importance when complications such as GvHD or VOD arise.
Authors: A Baumgartner; A Bargetzi; N Zueger; M Bargetzi; M Medinger; L Bounoure; F Gomes; Z Stanga; B Mueller; P Schuetz Journal: Bone Marrow Transplant Date: 2017-01-09 Impact factor: 5.483
Authors: Tiago Nava; Marc Ansari; Jean-Hugues Dalle; Christina Diaz de Heredia; Tayfun Güngör; Eugenia Trigoso; Ulrike Falkenberg; Alice Bertaina; Brenda Gibson; Andrea Jarisch; Adriana Balduzzi; Halvard Boenig; Gergely Krivan; Kim Vettenranta; Toni Matic; Jochen Buechner; Krzysztof Kalwak; Anita Lawitschka; Akif Yesilipek; Giovanna Lucchini; Christina Peters; Dominik Turkiewicz; Riitta Niinimäki; Tamara Diesch; Thomas Lehrnbecher; Petr Sedlacek; Daphna Hutt; Arnaud Dalissier; Jacek Wachowiak; Isaac Yaniv; Jerry Stein; Koray Yalçin; Luisa Sisinni; Marco Deiana; Marianne Ifversen; Michaela Kuhlen; Roland Meisel; Shahrzad Bakhtiar; Simone Cesaro; Andre Willasch; Selim Corbacioglu; Peter Bader Journal: Bone Marrow Transplant Date: 2020-02-06 Impact factor: 5.483
Authors: Ana Cláudia Thomaz; Carolline Ilha Silvério; Denise Johnsson Campos; Elena Emilia Moreira Kieuteka; Estela Iraci Rabito; Vaneuza Araújo Moreira Funke; Regina Maria Vilela Journal: Support Care Cancer Date: 2015-07-21 Impact factor: 3.603
Authors: Amro Mohamed Sedky El-Ghammaz; Rima Ben Matoug; Maha Elzimaity; Nevine Mostafa Journal: Support Care Cancer Date: 2017-04-24 Impact factor: 3.603
Authors: Gisele Trennepohl da Costa Heinen; Daniella Schmit; Denise Johnsson Campos; Carmem Bonfim; Estela Iraci Rabito; Regina Maria Vilela Journal: Support Care Cancer Date: 2017-10-03 Impact factor: 3.603
Authors: Erika Elias Ferreira; Daiane Cristina Guerra; Kátia Baluz; Wander de Resende Furtado; Luis Fernando da Silva Bouzas Journal: Rev Bras Hematol Hemoter Date: 2014-07-18